BRISTOL MYERS SQUIBB CO

BMY | NYSE | CIK: 0000014272 | SIC: 2834 Pharmaceutical Preparations | active
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular conditions, immunology, and fibrosis. Key marketed products include Revlimid, Eliquis, Opdivo, Pomalyst, Orencia, Sprycel, Yervoy, Abraxane, and Empliciti. The company engages in extensive R&D, strategic alliances, licensing arrangements, and global manufacturing to bring therapies to patients worldwide.
oncologycardiovascularimmunologyfibrosishematology
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/BMY
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
RevlimidserviceTreatment for multiple myeloma and other hematological cancers.
EliquisserviceAnticoagulant for stroke prevention and treatment of blood clots.
OpdivoserviceImmune checkpoint inhibitor for multiple oncology indications.
PomalystserviceTreatment for relapsed or refractory multiple myeloma.
OrenciaserviceBiologic treatment for rheumatoid arthritis and psoriatic arthritis.
SprycelserviceTargeted therapy for chronic myeloid leukemia.
YervoyserviceImmunotherapy for melanoma and other cancers.
AbraxaneserviceChemotherapy for breast, lung, and pancreatic cancers.
EmplicitiserviceTreatment for relapsed or refractory multiple myeloma.

Partnerships

PartnerTypeDescription
PfizerstrategicCo-development and commercialization alliance for Eliquis.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/BMY/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub